Bradley Canino
Stock Analyst at Stifel
(1.64)
# 3,380
Out of 5,026 analysts
88
Total ratings
32.91%
Success rate
-1.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $15.05 | +192.36% | 7 | Sep 10, 2025 | |
| JANX Janux Therapeutics | Reinstates: Buy | $45 | $27.20 | +65.44% | 3 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $4.18 | +258.85% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.65 | -9.09% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $8.74 | +117.39% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $6.51 | +253.30% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $9.68 | +426.86% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $10.13 | +87.56% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $52.53 | -20.05% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $21.97 | +82.07% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $90.42 | +49.30% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $13.30 | +50.38% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.35 | +198.51% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.56 | +541.03% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $94.88 | +4.34% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.48 | +464.52% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $60.46 | -9.03% | 4 | Feb 23, 2024 |
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $15.05
Upside: +192.36%
Janux Therapeutics
Sep 10, 2025
Reinstates: Buy
Price Target: $45
Current: $27.20
Upside: +65.44%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $4.18
Upside: +258.85%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.65
Upside: -9.09%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $8.74
Upside: +117.39%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $6.51
Upside: +253.30%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $9.68
Upside: +426.86%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $10.13
Upside: +87.56%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $52.53
Upside: -20.05%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $21.97
Upside: +82.07%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $90.42
Upside: +49.30%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $13.30
Upside: +50.38%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $3.35
Upside: +198.51%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.56
Upside: +541.03%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $94.88
Upside: +4.34%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.48
Upside: +464.52%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $60.46
Upside: -9.03%